CD274 and bacterial infectious disease: Consistently, our study demonstrated a significant improvement in bacterial clearance and reduced inflammation following anti-PD-L1 monoclonal antibody therapy for PM2.5-exposed mice, suggesting that targeting PD-L1 may be a promising therapeutic strategy to alleviate bacterial infection vulnerability provoked by PM2.5 exposure.